Latest From Alcobra Ltd.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Alcobra Ltd.
- Senior Management
Tomer Berkovitz, PhD, CFO
Jonathan Rubin, MD, CMO
David C Baker, Chief Commercial Officer
- Contact Info
Phone: 72-220 4661
132 Derech Menachem Begin
Tel Aviv, 6701101
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.